Esperion Therapeutics Inc
$ 3.15
0.32%
11 Jun - close price
- Market Cap 809,157,000 USD
- Current Price $ 3.15
- High / Low $ 3.15 / 3.14
- Stock P/E N/A
- Book Value -1.23
- EPS N/A
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.12 %
- ROE -2.61 %
- 52 Week High 4.17
- 52 Week Low 0.95
About
Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.
Analyst Target Price
$3.19
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-08 | 2026-03-10 | 2025-11-06 | 2025-08-05 | 2025-05-06 | 2025-03-04 | 2024-11-07 | 2024-08-12 | 2024-05-07 | 2024-02-27 | 2023-11-07 | 2023-08-01 |
| Reported EPS | -0.1 | 0.22 | -0.16 | -0.02 | -0.21 | -0.1013 | -0.15 | -0.05 | 0.34 | -0.5 | -0.37 | -0.46 |
| Estimated EPS | -0.0025 | 0.28 | -0.08 | -0.16 | -0.15 | -0.1575 | -0.17 | -0.17 | -0.01 | -0.48 | -0.42 | -0.63 |
| Surprise | -0.0975 | -0.06 | -0.08 | 0.14 | -0.06 | 0.0562 | 0.02 | 0.12 | 0.35 | -0.02 | 0.05 | 0.17 |
| Surprise Percentage | -3900% | -21.4286% | -100% | 87.5% | -40% | 35.6825% | 11.7647% | 70.5882% | 3500% | -4.1667% | 11.9048% | 26.9841% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.07 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ESPR
2026-06-09 19:39:01
Esperion Therapeutics announced that Germany's competition authority has approved its planned merger with Essence Parent Inc., an affiliate of ArchiMed SAS. This clearance satisfies a key regulatory condition for the merger, which still requires approvals under the U.S. Hart-Scott-Rodino Act and Esperion stockholder approval at a virtual special meeting on July 8, 2026. The merger would result in Esperion becoming a wholly-owned subsidiary of Essence Parent Inc.
2026-06-09 02:09:15
Glazer Capital, LLC and Paul J. Glazer have disclosed an 8.15% passive stake in Esperion Therapeutics, Inc. (ESPR), holding 20,975,620 shares. This information was reported in a Schedule 13G filing with the SEC, indicating shared voting and dispositive power over the shares managed by Glazer-managed funds. The filing specifies that Glazer Capital Enhanced Master Fund, Ltd. has the right to receive proceeds from the sale of these securities.
2026-06-06 13:11:28
Esperion Therapeutics (ESPR) shares dropped over 6% after reporting mixed Q4 earnings, with EPS below expectations but revenue slightly above. Despite the stock's fall, retail investors on Stocktwits remained highly bullish, citing future catalysts like U.S. market expansion, progress on a triple-combination program, and the acquisition of Corstasis Therapeutics. The company's CEO emphasized a long-term strategy for growth and value creation.
2026-06-02 11:39:51
J. Martin Carroll, a director at Esperion Therapeutics (ESPR), received an equity award of 79,873 shares of common stock at no cash cost. This grant, which increases his direct holdings to 177,523 shares, will fully vest on the earlier of May 28, 2027, or the company’s next annual meeting after May 28, 2026. This transaction was reported in a Form 4 filing, indicating a compensation-related acquisition under transaction code A.
2026-06-02 11:10:57
Esperion Therapeutics, Inc. (NASDAQ: ESPR) filed an 8-K report on May 28, 2026, detailing the results of its Annual Meeting of Stockholders. Key outcomes included the election of Class I directors, approval of executive compensation, ratification of Ernst & Young LLP as auditor, and a significant amendment to the 2022 Stock Option & Incentive Plan, increasing authorized shares by 7,000,000. This amendment, which brings the total maximum shares to 30,150,000, could lead to dilution for existing shareholders but also signals the company's intent to retain and attract talent or support growth initiatives.
2026-06-01 20:40:58
Esperion Therapeutics director John Craig Thompson has received a grant of 79,873 shares of common stock as compensation. The award has a reported price of $0.00 per share and will vest in full either on May 28, 2027, or the company's next annual meeting of stockholders following May 28, 2026, whichever comes first. This transaction is classified as an equity compensation grant, not an open-market purchase.
